A LinkedIn post from Pulnovo Medical highlights the company’s plans to showcase its pulmonary hypertension (PH) and heart failure (HF) technology at IndiaLive2026 in New Delhi. The post points to a live PADN procedure transmission on March 21 and presentations on the rationale, evidence, and case management of PADN for PH on March 20 and 21.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The content suggests Pulnovo is prioritizing clinical visibility and physician engagement in a major emerging market, which could support broader adoption of its PADN technology if clinical feedback is positive. Greater exposure among interventional cardiologists and key opinion leaders in India may help the company build references, support future trial enrollment, and lay groundwork for potential commercialization pathways in the region.
By emphasizing “redefining the standard of care” in pulmonary hypertension, the post underscores Pulnovo’s strategic positioning as an innovator in MedTech for PH and HF. For investors, sustained participation in high-profile scientific forums may be an indicator of the company’s efforts to strengthen its clinical evidence base, differentiate its technology versus competitors, and enhance its long-term partnership and market access prospects.